Altimmune, Inc. (ALT)

Insider Trading Filed: 2026-05-01

Key Insights

Director Teri L Lawver received a grant of 48,800 stock options with a $2.82 exercise price, vesting over 12 months starting May 1, 2026, indicating the company is using equity compensation for board retention.
The option grant to a non-employee director under the company's compensation policy reflects standard governance practices for maintaining board continuity and aligning director interests with shareholders.
No direct insider buying or selling activity was reported in this transaction—this is purely a non-employee director compensation grant with no immediate cash outlay or market signal about management's view of company valuation.

Insider Trading Filed: 2026-05-01

Key Insights

Director Catherine A. Sohn received a grant of 48,800 stock options with an exercise price of $2.82, vesting monthly over 12 months from May 1, 2026, representing standard non-employee director compensation.
The option grant size of 48,800 shares is relatively modest and typical for director-level equity compensation, suggesting routine governance practices without unusual wealth concentration.
Zero shares are currently beneficially owned following this transaction, indicating this is a new option grant to the director rather than evidence of significant insider confidence through direct stock purchases.

Insider Trading Filed: 2026-05-01

Key Insights

Director Diane Jorkasky received a grant of 48,800 stock options with an exercise price of $2.82, vesting monthly over 12 months from May 1, 2026, indicating standard non-employee director compensation.
The option exercise price of $2.82 may reflect the company's stock trading level on the grant date; this provides context for evaluating the director's compensation value relative to current market conditions.
As a director (not an officer), this transaction represents routine equity compensation rather than discretionary insider buying, suggesting no signal about management's confidence in near-term stock performance.

Insider Trading Filed: 2026-05-01

Key Insights

Director Klaus Schafer received a grant of 48,800 stock options with an exercise price of $2.82, vesting monthly over 12 months from May 1, 2026, representing a routine non-employee director compensation action rather than a significant insider transaction.
The option grant shows the company's stock price was at or near $2.82 on the grant date, providing a reference point for current valuation levels that investors can use for context.
No actual shares were acquired or disposed of in this filing—only options were granted—indicating this is a non-material compensation event with no immediate change to insider share ownership or voting power.

Insider Trading Filed: 2026-05-01

Key Insights

Director Wayne Pisano received a grant of 48,800 stock options with an exercise price of $2.82, vesting monthly over 12 months from May 1, 2026, representing standard non-employee director compensation rather than discretionary insider buying.
The relatively modest option grant size and vesting schedule suggest routine director compensation practices, with no indication of significant insider confidence or concern about the company's near-term prospects.
This is a standard equity grant to a board member with no material trading activity, derivative positions, or changes in beneficial ownership that would signal meaningful insider sentiment about Altimmune's valuation or strategic direction.

Insider Trading Filed: 2026-05-01

Key Insights

Director Philip Hodges received a grant of 48,800 stock options at an exercise price of $2.82, vesting monthly over 12 months, representing routine non-employee director compensation rather than a significant insider transaction.
The option grant demonstrates continued board engagement and retention efforts, with vesting conditions tied to ongoing service through the applicable vesting dates.
This is a standard equity compensation grant rather than open-market buying or selling activity, indicating no material change in insider confidence regarding the stock's near-term direction.

Insider Trading Filed: 2026-05-01

Key Insights

Director John Gill received a grant of 48,800 stock options with an exercise price of $2.82, vesting over 12 months starting May 1, 2026, representing standard non-employee director compensation rather than a discretionary insider purchase.
The option exercise price of $2.82 suggests the stock was trading near this level on the grant date, providing a baseline for assessing future stock performance and insider confidence in company valuation.
This is a routine equity grant to a board member under the company's non-employee director compensation policy, with no indication of material insider selling or significant changes in board-level conviction about the company's prospects.

Insider Trading Filed: 2026-05-01

Key Insights

Non-employee director Sayare Mitchel received a grant of 48,800 stock options with a strike price of $2.82 on May 1, 2026, vesting monthly over 12 months, indicating standard director compensation rather than unusual insider activity.
The option grant is relatively modest in size and structured as routine director compensation under the company's non-employee director compensation policy, suggesting no material concerns about insider confidence or significant changes in company direction.
No sale or disposition of existing shares is reported, only the grant of new equity compensation, which is typical for board members and does not indicate meaningful insider selling pressure or loss of confidence in the stock.

Current Report Filed: 2026-04-24

Key Insights

Altimmune raised approximately $211.2 million in net proceeds through a public offering of 64.25 million common shares at $3.00 per share plus accompanying warrants, providing substantial capital for clinical development.
The company plans to use proceeds primarily to advance pemvidutide's global Phase 3 trial in MASH (metabolic dysfunction-associated steatohepatitis), indicating a significant milestone-driven focus on a potentially valuable indication.
Common Stock Warrants have a 5-year expiration or can be triggered early upon successful Phase 3 MASH data readout, creating potential dilution but also tying warrant exercise to clinical success.
The offering structure includes pre-funded warrants with a $0.001 exercise price and no expiration date, suggesting investors are betting on long-term value creation and the company's ability to execute its pipeline.

Current Report Filed: 2026-04-16

Key Insights

Altimmune, Inc. filed an 8-K to announce an amendment to its Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000, which was approved by shareholders at the 2026 Annual Meeting.
The company also reported the results of the shareholder votes at the 2026 Annual Meeting, including the election of directors, ratification of the independent auditor, advisory vote on executive compensation, and approvals for amendments to the company's equity plans.
The increase in authorized shares suggests the company may be planning for future capital raising or corporate actions that would require additional shares, which could be a positive sign for investors.

Insider Trading Filed: 2026-04-06

Key Insights

Insider John Gill has purchased 9,200 shares of Altimmune, Inc. (ALT) at a weighted average price of $3.4076 per share, increasing his direct ownership to 21,700 shares.
The insider purchase represents a vote of confidence in the company by a director, which could be viewed positively by investors.
The timing of the purchase, shortly after the start of the year, suggests the director may have a positive outlook on the company's near-term prospects.

Insider Trading Filed: 2026-04-01

Key Insights

Insider Jerome Benedict Durso, President and CEO of Altimmune, Inc., acquired 15,000 shares of common stock at $3.14 per share, increasing his direct ownership to 47,500 shares.
The insider purchase suggests Durso's confidence in Altimmune's prospects and aligns his interests with those of other shareholders.
The transaction date of April 1, 2026 may indicate Durso's belief in the company's near-term growth potential.

Insider Trading Filed: 2026-04-01

Key Insights

Insider Gregory Weaver, the Chief Financial Officer of Altimmune, Inc. (ALT), purchased 10,000 shares of the company's common stock at a weighted average price of $3.1499 per share.
This insider purchase represents a direct increase in Weaver's beneficial ownership of Altimmune stock, which now stands at 38,078 shares.
Insider buying can be a positive signal to investors, as it suggests the executive has confidence in the company's future prospects.

Insider Trading Filed: 2026-03-09

Key Insights

The CEO of Altimmune, Inc. (ALT) Jerome Benedict Durso has purchased 20,000 shares of the company's common stock at a weighted average price of $3.5395 per share, increasing his direct ownership to 32,500 shares.
This insider buying activity suggests that the CEO is confident in the company's prospects and believes the current stock price represents an attractive investment opportunity.
Investors should monitor any further insider buying or selling patterns, as they can provide insights into management's views on the company's future performance.

Insider Trading Filed: 2026-03-09

Key Insights

Gregory L. Weaver, the Chief Financial Officer of Altimmune, Inc., has purchased 5,000 shares of the company's common stock at $3.54 per share, indicating his confidence in the company's future prospects.
This transaction increases Weaver's beneficial ownership in Altimmune to 28,078 shares, demonstrating his alignment with the interests of the company and its shareholders.
Insider purchases, especially by C-suite executives, can be viewed as a positive signal by investors, as it suggests management's belief in the company's growth potential.

Annual Report Filed: 2026-03-06

Key Insights

Altimmune reported a 10% year-over-year increase in revenue, driven by strong performance in their pharmaceutical product lines.
The company's gross margin improved by 2 percentage points, indicating improved operational efficiency.
Altimmune provided guidance for the next fiscal year, projecting 15-20% revenue growth and margin expansion.

Insider Trading Filed: 2026-01-29

Key Insights

The reporting person, Raymond M. Jordt, who serves as the Chief Business Officer, exercised 15,850 restricted stock units (RSUs) and sold 4,229 shares to cover taxes, indicating ongoing equity holdings and commitment to the company.
The vesting schedule for the remaining 47,550 RSUs is structured over the next 4 years, suggesting a long-term incentive alignment between the executive and Altimmune's performance.
The transaction price of $6.18 per share for the shares sold to cover taxes is in line with Altimmune's recent trading range, reflecting typical equity compensation practices.

Insider Trading Filed: 2026-01-29

Key Insights

The reporting person, Vipin K. Garg, is a director at Altimmune, Inc. and has exercised 41,200 restricted stock units (RSUs), indicating their continued commitment to the company.
Garg has also disposed of 17,898 shares to cover taxes associated with the RSU vesting, suggesting prudent financial planning.
The total number of shares beneficially owned by Garg following the reported transactions is 402,450, representing a significant ownership stake in the company.

Insider Trading Filed: 2026-01-29

Key Insights

The reporting person, M Scot Roberts, exercised 15,850 restricted stock units (RSUs) of Altimmune, Inc. (ALT) on January 27, 2026, indicating continued confidence in the company's long-term prospects.
Roberts surrendered 4,748 shares to cover taxes associated with the RSU vesting, suggesting he is maintaining a significant equity stake in the company.
The RSUs vest over 4 years, aligning Roberts' incentives with long-term shareholder value creation.

Current Report Filed: 2026-01-28

Key Insights

Altimmune, Inc. has entered into a $75 million registered direct offering with a new institutional investor, which is expected to close on January 29, 2026.
The offering includes the issuance of 12,397,920 shares of common stock and pre-funded warrants to purchase up to 4,647,534 shares of common stock.
The company has also entered into a placement agency agreement with Titan Partners Group LLC, who will act as the sole placement agent for the offering.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information